Metformin and it's role in the management of type-2 diabetes;Die stellung der biguanide in der therapie des diabetes mellitus

Medizinische Klinik

Volumn 92, Issue 8, 1997, Pages 472-479

  Haupt, Ekke ^a,c   Panten, Uwe ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Saale Klinik der BfA   (Germany)

Author keywords

Effects on insulin resistance factors; Lactic acidosis; Metformin; Type 2 diabetes

Indexed keywords

ACARBOSE; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DRUG MECHANISM; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LACTIC ACIDOSIS; MAJOR CLINICAL STUDY; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; REVIEW; TREATMENT INDICATION;

EID: 0030884723     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03044916     Document Type: Review

References (64)

1. Alberti, K. G. M. M., F A. Gries, J. Jerwell, A. M. J. Krans für die NIDDM-Policy Group: Leitfaden für die Betreuung des nicht-insulinabhängigen Diabetes mellitus (NIDDM, Typ 2) Deutsche Übersetzung der 2. Auflage, Mainz-Kirchheim 1994.
2. Assan, R., C. H. Heuclin, D. Ganeval, C. H. Bismuth, J. George, J. R. Girard. Metformin induced lactic acidosis in the presence of renal failure, Diabetologia 13 (1977), 211-217.
3. Bailey, C. J.: Biguanides and NIDDM. Diabet, Care 15 (1992), 755-772.
4. Bailey, C. J.: Metformin - an update. Gen Pharmacol. 24 (1993), 1299-1309.
5. Bailey, C. J , K J. Mynett: Insulin requirement for the antihyperglycaemic effect of metformin. Brit. J. Pharmacol. 111 (1994), 793-796.
6. Bailey, C. J., K. J. Mynett, T. Page: Importance of the intestine as a site of metformin-stimulated glucose utilization. Brit. J. Pharmacol. 112 (1994), 671-675
7. Berger, W.: Incidence of severe side effects during therapy with sulfonylureas and biguanides. Horm. metab. Res. 15 (1985), 111-115.
8. Campbell, I. W.: Metformin and glibenclamide: Comparative risks: Brit. Med. J. 289 (1984), 289.
9. Campbell, I. W.: Metformin and the sulphonylureas. The comparative risk. Horm. met. Res. 15 (1985), 105-111.
10. Campbell, I. W., C. Duncan, N. W. Patton, T. Broadhead, G. T. Tucker, H. F. Woods: The effect of metformin on glycaemic control, intermediary metabolism and blood pressure in non-insulin-dependent diabetes mellitus. Diabet. Med. 4 (1987), 337-343.
11. Campbell, I. W.: Management of typ 2 diabetes mellitus with special reference to metformin therapy. Diabète et Metab. 17 (1991), 191-196.
12. Campbell, I. W., H. C S. Howlett: Worldwide experience as an effective glucose lowering agent: A meta-analysis 1994, in press.
13. Clarke, B. F., L J. P Duncan. Comparison of chlorpropamide and metformin treatment on weight and blood-glucose response of uncontrolled obese diabetics. Lancet I (1968), 123-126.
14. Clarke, B. F., I. W. Campbell. Comparison of metformin and chlorpropamide in non obese, maturity-onset diabetics uncontrolled by diet. Brit. med. J. 2 (1977), 1576-1578.
15. Cohen, R. D.: The relative risks of different biguanides in the causation of lactic acidoses. Res. clin. For. 1 (1979), 125-134.
16. Collier, A., H. H. K. Watson, A. W. Patrick, C. A. Ludlam, B. F. Clarke: Effect of glycaemic control, metformin and ghclazide on platelet density and aggregability in recently diagnosed type 2 (non-insulin-dependent) diabetic patients. Diabète et Metab. 15 (1989), 420-425
17. de Fronzo, R. A , N. Barzilai, D. C. Simonson: Mechanism of metformin action in obese and lean non-insulin-dependent diabetic subjects. J. clin. Endocr. 73 (1991), 1294-1301.
18. de Fronzo, R. A., A. Goodman, Metformin investigator group Combined metformin glyburide treatment in NIDDM patients not optimally responding to maximum dose sulfonylurea. Results of a multicenter trial. Diabetes 42, Suppl. 1 (1993), 14.
19. Ernährungsabhängige Krankheiten und ihre Kosten. Schriftenreihe des Bundesministeriums fur Gesundheit, Bd 27. Nomos, Baden-Baden 1993.
20. Fantus, I. G., R. Brosseau: Mechanism of action of metformin: Insulin receptor effects in vitro and in vivo. J. clin. Endocr. 63 (1986), 898-905.
21. Ferner, R. E., M. D. Rawlins, K. G M M. Alberti: Impaired alpha cell responses improve when fasting blood glucose concentration is reduced in non-insulin-dependent diabetes. Quart. J. Med. 250 (1988), 137-146.
22. Gin, H , C. Freyburger, M. Boisseau, J Aubertin: Effect of metformin on platelet hyperaggregation in the insulin-dependent diabetic. Diabète et Metab. 14 (1988), 596-600.
23. Giugliano, D., A. Quatraro, G. Consoli, A. Minei, A. Ceriello, N. De Rosa, F. D. Onofrio. Metformin for obese, insulin-treated diabetic patients: Improvement in glycaemic control and reduction of metabolic risk factors. Europ. J. clin. Pharmacol. 44 (1993), 107-112.
24. Goodman, A. M.: Efficacy and safety of metformin: Results of a multicenter trial Diabetes 42, Suppl. 1 (1993), 57.
25. Grant, P. J., M. H. Stickland, N. A. Booth, C. R. M. Prentice: Metformin causes a reduction in basal and postvenous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. Diabet. Med. 8 (1991), 361-365.
26. Grant, P. J.: The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. Diabète et Metab. 17 (1991), 168-173.
27. Haupt, E , B. Knick, Koschinsky, H. Liebermeister J, Schneider, H. Hirche: Oral antidiabetic combination therapy with sulphonylureas and metformin. Diabète et Metab. 17 (1991), 224-231
28. Hermann, L S.: Metformin. A review of its pharmakological properties and therapeutic use. Diabète et Metab. 5 (1979), 233-245.
29. Hermann, L. S , P. O. Bitzen, T. Kiellström, U Lindgarde, N. Schersten: Comparative efficacy of metformin and glibenclamide in patients with non-insulin-dependent diabetes mellitus. Diabète et Metab. 17 (1991), 201-208.
30. Hermann, L. S , B. Schersten, P -O. Biten, T. Kiellstrom, F. Lindgarde, A. Melander: Therapeutic comparisom of metformin and sulfonylurea, alone and in various combinations. A double blind controlled study. Diabet. Care 17 (1994), 1100-1109.
31. Hollenbeck, C. B , P Johnston, B. B. Varasteh, Y. D. I. Chen, G M. Reaven: Effects of metformin on glucose, insulin and lipid metabolism in patients with mild hypertriglyceridaemia and non-insulin dependent diabetes by glucose tolerance test criteria. Diabète et Metab. 17 (1971), 483-489.
32. Howard, B. V.: Lipoprotein metabolism in diabetes mellitus. J. Lipid Res. 28 (1987), 613.
33. Johnston, P., W. H. Sheu, C. B. Hollenbeck, C. Y. Jeng, I. D. Goldfine, Y. D Chen, G M. Reaven: Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabet. Care 13 (1990), 1-8.
34. Josephkutty S., J. M. Potter: Comparison of tolbutamide and metformin in elderly diabetic patients. Diabet. Med. 7 (1990), 510-514.
35. Klein, W.: Sulfonylurea-metformin-combination versus sulfonylurea-insulin-combination in secondary failures of sulfonylurea monotherapy. Diabète et Metab. 17 (1991), 235-240.
36. Koschinski, P., C. E. Bünting, R. Rüttler, F. A. Gries: Influence of metformin on vascular cell proliferation. Diabète et Metab. 14 (1988), 566-570.
37. 36a Krönke H.: Langzeitergebnisse bei Sekundärversagern mit einer Kombinationstherapie von Glibenclamid und Metormin im Vergleich zur Insulintherapie Der Kassenarzt 30 (1990), 38-43.
38. Lalor, B C., D. Bhatnagar, P. H. Winnocour, M. Ishola, S. Arrol, M. Brading, P. N. Durrington: Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients. Diabet. Med. 7 (1990), 242-256.
39. Lim, P., O. T. Khoo: Metformin compared with tolbutamide in the treatment of maturity onset diabetes mellitus. Med J. Aust. 1 (1970), 271-273.
40. Lord, J. M., S. I White, C. J. Bailey, T. W. Atkins, R. F. Fletcher, K. G. Taylor: Effect of metformin insulin receptor binding and glycaemic control in type 2 diabetes. Brit. med. J. 286 (1983), 830-831
41. Lucis, O J. The status of metformin in Canada. Canad. med. Ass. J. 128 (1983), 24-26.
42. Luft, D., R M. Schmülling, M. Eggstein: Lactic acidosis in biguanide treated diabetes. A review of 330 cases. Diabetologia 14 (1978), 75-87.
43. Massad, L , M Plotkine, M. Allix, R. G. Boulu: Antithrombotic drugs in a carotid occlusion model: Beneficial effect of the antidiabetic agent metformin. Diabète et Metab. 14 (1988), 544-548.
44. Michaelis, D., E. Jutzi: Epidemiologie des Diabetes mellitus in der Bevolkerung der ehemaligen DDR: Alters-und geschlechtsspezifische Inzidenz-und Pravalenztrends un Zeitraum von 1960-1987 Z klin. Med (1991), 59-64.
45. Nattrass, M., K G. M. M. Alberri. Biguanides. Diabetologia 14 (1978). 71-74
46. Nagi, D K., J S Judkin: Effects of metformin on insulin resistance, risk factors for cardiovascular disease and plasminogen activator inhibitor in NIDDM subjects. Diabet Care 16 (1993), 621-629.
47. Nosadini, R , A. Avogaro, R. Trevisan: Effect of metformin on insulin stimulated glucose turnover and insulin binding to receptors in type 2 diabetes Diabet Care 10 (1987). 62-67
48. Noury, J., A. Nandevil: Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDDM. Diabète et Metab. 17 (1991), 209-212.
49. Perriello, G., P, Misericordia, E. Volpi, A. Santucci, C. Santucci, P. Ferrannini, M. M. Ventura, F. Santensanio, P. Brunetti, G. B Bolli: Acute antihyperglycemic mechanisms of metformin in NIDDM. Diabetes 43 (1994), 920-924.
50. Prager, R., G. Schemthaner: Insulin receptor binding to monocytes, insulin secretion and glucose tolerance following metfomin treatment: Results of a doubleblind cross-over study in type 2 diabetics. Diabetes 32 (1983), 1083-1086.
51. Prager, R., G. Schernthaner, H. Graf: Effect of metformin on peripheral insulin sensitivity in non msulin dependent diabetes mellitus. Diabète et Metab. 12 (1986), 346-350.
52. Rains, S. G. H., G. A. Wilson, W. Richmond, R. S. Elkeles. The effect of glibenclamide and metformin on serum hpoproteins in type 2 diabetes. Diabet. Med. 5 (1988), 653-658.
53. Ritzkalla, S. W., F. Elgrably, G Tchobroutsky, G. Slama: Effects of metformin treatment on erythrocyte insulin binding in normal weight subjects, in obese non-diabetic subjects and type 1 and type 2 diabetic patients. Diabète et Metab. 12 (1986), 219-224.
54. Rote Lute, Arzneimittelverzeichnis des BPI. Edition Cantor, Aulendorf 1994.
55. Schatz, H., S Doci, R. Höfer. The effect of dimethylbiguanide on glucose tolerance, seruminsulin and growth hormone in obese patients, Diabetologia 8 (1972), 1-7.
56. Schatz, H., N. Katsilambros, C. Nierele, E. U. Pfeiffer: The effect of biguanides on secretion and biosynthesis of insulin in isolated pancreatic islets of rats. Diabetologia 8 (1972), 402-407.
57. Schäfer, G.: Biguanides. A review of history, pharmacodynamics and therapy. Diabète et Metab. 9 (1983), 148-163.
58. Schernthaner, G , G. M. Kostner, H. Dieplinger, R. Prager, I. Muhlhauser. Apolipoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: cholesterol-acyltransferase activity in diabetes mellitus. Atherosclerosis 49 (1983), 277-293.
59. Schemthaner, G., T. H Vukovich, C. H. Gisinger: Anomalies de l'hemostase au cours du diabète sucre. Flammarion Med. Sci J. Diabet. (1991), 91-108.
60. Scherntharier, G.: Kritische Analyse der antidiabetischen Therapie mit Metformin: Stoffwechselwirkungen, antiatherogene Effekte und Kontraindikationen. Akt. Endokr. Stoffw. 13 (1993), 44-50.
61. Schneider, J.: Effects of metformin on dyslipoproteinemia in non-insulin-dependent diabetes mellitus. Diabète et Metab. 17 (1991), 185-190.
62. Sirtori, C. R., E. Tremoli, M. Sirtori, U. Conti, R. Paoletti Treatment of hypertriglyceridemia with metformin: Atherosclerosis 26 (1977), 583-586.
63. Slama, G.: The insulin sparing effect of metformin in insulin treated diabetic patients Diabète et Metab. 17 (1991), 241-243.
64. Standl, R., H. Snegler, B. Rebell, A.-G. Ziegler, G. Schauer, R. Roth, K. Schulz, W. Lehmacher, E. Standl: Der Typ II-Diabetes in der Praxis des niedergelassenen Arztes, Konzept einer zentrumgestützten Betreuung und Ergebnisse einer Stichprobenerhcbung im Großraum Munchen. Akt Endokr. Stoffw. 11 (1990), 222-227